UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Third International Pediatric Consensus statement on the management of childhood asthma

Pediatric pulmonology, 1998-01, Vol.25 (1), p.1-17

1998

Volltextzugriff (PDF)

Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101

Cancer chemotherapy and pharmacology, 2004-06, Vol.53 (6), p.482-488

2004

Volltextzugriff (PDF)

G475(P) Measuring neurodevelopmental outcomes of prematurity- before and after a neurodevelopmental follow-up service

Archives of disease in childhood, 2017-05, Vol.102 (Suppl 1), p.A187-A187

2017

Volltextzugriff (PDF)

Measuring neurodevelopmental outcomes of prematurity-before and after a neurodevelopmental follow-up service

Archives of disease in childhood, 2017-05, Vol.102 (5), p.A187

2017

Volltextzugriff (PDF)

G431(P) Audit on looked after children at risk of blood–borne infections

Archives of disease in childhood, 2015-04, Vol.100 (Suppl 3), p.A178-A179

2015

Volltextzugriff (PDF)

G576(P) Looked after children at risk of blood-borne infections: a quality improvement audit

Archives of disease in childhood, 2015-04, Vol.100 (Suppl 3), p.A262-A262

2015

Volltextzugriff (PDF)

Effectiveness of bronchodilators in cystic fibrosis

The American journal of medicine, 1996-01, Vol.100 (1A), p.S19-S29

Cropp, Gerd J.

1996

Volltextzugriff (PDF)

Results of a Phase I Dose-escalating Study of the Antiangiogenic Agent, SU5416, in Patients with Advanced Malignancies

Clinical cancer research, 2002-09, Vol.8 (9), p.2798-2805

2002

Volltextzugriff (PDF)

Regional differences in prevalence and risks of respiratory diseases in children

Pediatric pulmonology, 1999, Vol.27 (S18), p.37-40

Cropp, Gerd J.

1999

Volltextzugriff (PDF)

Evaluation of a family asthma program

Journal of allergy and clinical immunology, 1984-10, Vol.74 (4), p.505-510

1984

Volltextzugriff (PDF)

Reflections and farewell

Pediatric pulmonology, 2002-07, Vol.34 (1), p.1-1

Cropp, Gerd

2002

Volltextzugriff (PDF)

Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors

Journal of clinical oncology, 2002-03, Vol.20 (6), p.1657-1667

Kuenen, B. C.

2002

Volltextzugriff (PDF)

Phase I trial of NPI-2358 (a novel vascular disrupting agent) plus docetaxel

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.3571-3571

2009

Volltextzugriff (PDF)

Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.8505-8505

2009

Volltextzugriff (PDF)

The exercise bronchoprovocation test: Standardization of procedures and evaluation of response

Journal of allergy and clinical immunology, 1979-12, Vol.64 (6), p.627-633

Cropp, Gerd J.A.

1979

Volltextzugriff (PDF)

Phase I study of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.3525-3525

2008

Volltextzugriff (PDF)

Phase I trial of KOS-1584 (a novel epothilone) using two weekly dosing schedules

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.2571-2571

2007

Volltextzugriff (PDF)

Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): Pharmacology, safety and activity in relapsed/refractory (rel/ref) patients (Pts)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.3532-3532

2007

Volltextzugriff (PDF)

A phase 1 dynamic accelerated titration dose escalation study of the vascular disrupting agent NPI-2358

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.14097-14097

2007

Volltextzugriff (PDF)

Special Features of Asthma in Children

Chest, 1985-01, Vol.87 (1), p.55S-62S

Cropp, Gerd J.A.

1985

Volltextzugriff (PDF)

Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416

Journal of pharmacy and pharmacology, 2001-12, Vol.53 (12), p.1629-1636

2001

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients With Advanced Solid Tumors

Journal of clinical oncology, 1999-04, Vol.17 (4), p.1095-1104

1999

Volltextzugriff (PDF)

A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM)

Blood, 2006-11, Vol.108 (11), p.406-406

2006

Volltextzugriff (PDF)

First-in-human phase I trial of a novel epothilone, KOS-1584

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.2003-2003

2006

Volltextzugriff (PDF)

Phase I trial of KOS-953, a heat shock protein 90 inhibitor, and trastuzumab (T)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.501-501

2006

Volltextzugriff (PDF)

1 – 25 von 304

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(246)
Mit Volltextzugriff
(247)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(133)
Life Sciences & Biomedicine
(120)
Humans
(101)
Female
(56)
Biological And Medical Sciences
(54)
Male
(50)
Medical Sciences
(41)
Animals
(39)
Child
(34)
Adolescent
(27)
Adult
(26)
Middle Aged
(23)
Aged
(20)
Pediatrics
(18)
Oncology
(17)
Physical Sciences
(17)
Child, Preschool
(16)
Infectious Diseases
(16)
Tropical Medicine
(15)
Fundamental And Applied Biological Sciences. Psychology
(14)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Third International Pediatric Consensus statement on the management of childhood asthma

Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101

G475(P) Measuring neurodevelopmental outcomes of prematurity- before and after a neurodevelopmental follow-up service

Measuring neurodevelopmental outcomes of prematurity-before and after a neurodevelopmental follow-up service

G431(P) Audit on looked after children at risk of blood–borne infections

G576(P) Looked after children at risk of blood-borne infections: a quality improvement audit

Effectiveness of bronchodilators in cystic fibrosis

Results of a Phase I Dose-escalating Study of the Antiangiogenic Agent, SU5416, in Patients with Advanced Malignancies

Regional differences in prevalence and risks of respiratory diseases in children

Evaluation of a family asthma program

Reflections and farewell

Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors

Phase I trial of NPI-2358 (a novel vascular disrupting agent) plus docetaxel

Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM)

The exercise bronchoprovocation test: Standardization of procedures and evaluation of response

Phase I study of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas

Phase I trial of KOS-1584 (a novel epothilone) using two weekly dosing schedules

Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): Pharmacology, safety and activity in relapsed/refractory (rel/ref) patients (Pts)

A phase 1 dynamic accelerated titration dose escalation study of the vascular disrupting agent NPI-2358

Special Features of Asthma in Children

Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416

Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients With Advanced Solid Tumors

A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM)

First-in-human phase I trial of a novel epothilone, KOS-1584

Phase I trial of KOS-953, a heat shock protein 90 inhibitor, and trastuzumab (T)

Suchergebnisse filtern